ArticleProceedings of the National Academy of Sciences of the United States of America2025
Reconsidering indoor residual spraying coverage targets: A retrospective analysis of high-resolution programmatic malaria control data.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Community-level barriers and facilitators of indoor residual spraying for malaria control: a systematic review of qualitative evidence from sub-Saharan Africa.Malaria journal · 2026Pooled it
- Impact of a one-year interruption to vector control on Bioko Island, Equatorial Guinea.Malaria journal · 2026Article
- Prediction of mosquito vector abundance for three species in the Anopheles gambiae complex.Parasites & vectors · 2025Article
- Impact of a one-year interruption to vector control on Bioko Island, Equatorial Guinea.medRxiv : the preprint server for health sciences · 2025Article
- Characterization ofInsects · 2025Article
- Testing indoor residual spraying coverage targets for malaria control, Bioko, Equatorial Guinea.Bulletin of the World Health Organization · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Indoor residual spraying (IRS) is one of the core vector control interventions available to malaria control programs. Normative and scientific guidance has long held that very high IRS coverage (at least 80 to 85% houses sprayed) is necessary to provide community protection, but there is little evidence backing these recommendations, in large part due to the operational and ethical concerns that conducting appropriate trials of differing IRS coverage levels would raise. The present study leverages data from four years of targeted IRS implementation on Bioko Island, Equatorial Guinea, to estimate a dose-response curve of IRS coverage. Due to the observational nature of the data, a double robust causal inference technique was utilized. The results suggest that at all spatial scales examined a threshold providing community protection was reached at much lower coverage levels than previously assumed (30 to 50%). Sensitivity analysis corroborated this result across multiple methods, but there was less agreement on whether extremely high coverage ([Formula: see text]85%) has additional benefit. A secondary analysis of the impact of changing operational coverage targets found that significantly reducing coverage targets (to 30 to 60%) could provide nearly the same protection as maintaining the existing 80% target in Bioko. While these findings are limited in strength by the observational nature of the data and may be specific to the context of Bioko Island, they raise important questions for further research on how IRS coverage impacts epidemiological outcomes and on how malaria control programs should set programmatic IRS coverage targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.